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after heterotopic heart transplantation in a murine model. Using the technique of mac- 
roarrays and immunohistochemistry, we have shown that MIP-1 b was over expressed 
and that VE-Cadherin was under expressed in the endothelial cells (ECs) of rejecting 
allografts. In this study, routrne endomyocardial biopsies were performed following 
human heart transplantation. Cardiac tissues were embedded I” paraffin for routine his- 
tologic analysis. Specimen was graded for AR using the ‘“ISHLT criteria. Immunohis- 
tochemical staining for the expression of MIP-lb and VE-Cadherln was performed I” 
cardiac tissues showing either no rejection (n=lO), rejection grade I6 @IO), or rejection 
grade IllA @lo). 
Results: MIP-1 p was strongly expressed (+++) on ECs in heart tissues showing an AR 
grade IIIA when compared to heart tissue showing grade I6 (++) AR or cardiac tissues 
with no AR (+). VE-Cadherin was detected as a thin, linear stainmg on ECs I” cardiac tis- 
sues showing no rejection (+++ or strongly positive). In contrast, the VE-Cadherin stain- 
ing was weak (+ or weakly positive) or completely absent on ECs present rn biopsies 
showing AR (grade IB and IIIA). 
Conclusions: We have identified and valrdated for the first time 2 genes (MIP-lb and 
VE-Cadherin) present in ECs lining the vessel walls, as markers of AR in human cardiac 
tissues. MIP-1 p, a chemokine, induces chemotaxis and adhesion of T-cells on ECs; VE- 
Cadherin, an endothelial-specific membrane protein responsible for the endothelial cell- 
cell adhesion, plays a key role in the migration of lymphocytes into myocardial tissues. 
Validated genes derived from the murine model can be used as potential targets in AR in 
human heart transplantation. 
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Background: Rejection surveillance is extensively based on routine endomyocardial 
biopsy (EMB) screenings. Nevertheless, routine EMBs are distressing to the patients and 
risky. To verify the possibility to replace routine EMB screenings by efficiently timed diag- 
nostic EMBs, we compared the diagnostic efficiency of routine EMBs with that of a com- 
bined, mainly non-invasive rejection surveillance-strategy, in which EMBs were 
performed optionally, only rn patients suspected for rejection. 
Methods: Two groups of patients underwent different rejection ‘surveillance strategies 
during their first post-transplant year. In group A (n ~76) we performed a telemetric mon- 
itoring of the intramyocardial electrogram (IMEG) from a dual-chamber pacemaker. 
Overnight IMEG changes were analyzed on daily printouts. Additional pulsed-wave tis- 
sue Doppler (PW-TD) wall motion analyses were performed daily during hospitalization 
and after discharge, at each ambulatory examination. In group B (n =22), additionally to 
IMEG recordings and PW-TD examinations, independent routine EMB screenings were 
performed at predefined time intervals. 
Results: In group A the mean number of EMBs per patient (1.45 kl.25) was 66.9% lower 
than the number of routine EMBs performed in each patient of group B. In group A, 
21 .I% of the patients had no relevant IMEG and/or PW-TD changes and therefore no 
EMBs. The average numbers of rejection therapies par patient performed in group A 
(0.74 +0.71) and group B (0.77 * 0.75 ), as well as the number of morphological signifi- 
cant (ISHLT grade > 2) rejection episodes per patient (0.16 * 0.15) in group A and 0.14 f 
0.13 in group B) were similar. In group 6 93.6% of the routine EMBs had no therapeutic 
consequences. In group A, 50.9% of rejection episodes, suspected by IMEG and/or PW- 
TDI changes and confirmed by EMBs, were clinically relevant and needed antirejection 
treatment. No patient died during the study. 
Conclusions: Non-invasive rejection surveillance based on IMEG recordings and tissue 
Doppler wall motion analyses in combination with diagnostic EMBs allow a reliable, effi- 
cient and save monitoring even during the first post-transplant year, without unnecessary 
and distressing routine EMBs. 
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Background: Routine surveillance endomyocardial biopsies (EMB) are commonly used 
to screen for cellular rejection in pediatric heart transplant patrents. With advances in 
immunosuppressron, the benefit of EMB in asymptomatic pediatric heart transplant 
patients is unclear. 
Methods: After orthotopic heart transplant (OHT), surveillance EMBs were routinely per- 
formed on all pediatric OHT patients with decreasing frequency. All biopsy specimens 
were reviewed by a cardiac pathologist, and graded according to International Society for 
Heart and Lung Transplantation (ISHLT) guidelines. A retrospective review of consecu- 
tive EMBs performed at our institution from January 1995 to September 2002 was con- 
ducted. The echocardiogram results, clinical history and treatment changes at the time of 
every biopsy were also recorded. 
Results: Results of 866 EMBs from 91 patients were reviewed. Two hundred and thirty- 
seven EMBs (23.9%) were performed within thirty-days of OHT, 394 EMBs (45.5%) were 
performed between one month and one year from OHT, and 265 EMBs (30.6%) were 
performed more than 1 year after OHT. Of all EMBs, 1.39% were ISHLT grade 2 or 
higher, 3.58% were grade 1 B, 19.4 % were grade IA, and 74.6% were grade 0. Six of the 
EM8 were unable to be interpreted because of insufficient tissue. Of the twelve patients 
in whom the EMB was read as grade 2 or higher, six were less than one month from OHT 
and asymptomatic. The other six patients with greater than 1B cellular rejection pre- 
sented for biopsy because of symptoms and had abnormal function on echocardiogram. 
Of the 820 EMB performed I” asymptomatic patients more than one month from OHT, 
there were no episodes of cellular rejection greater than IB. There were 21 asynIptOm- 
atic patient biopsies (2.56%) with grade IB rejection. All grade IB relection detected by 
surveillance EMB resolved in both treated and untreated cases. 
Conclusion: EMB should only be used to screen for cellular rejection in the first month 
after pediatric heart transplantation. For pediatric patients more than thirty days after 
OHT, EMB has failed to reveal significant episodes of cellular rejection in asymptomatic 
patients. The utility of surveillance EMB to detect humoral rejection was not assessed. 
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Although routine endomyocardial biopsies (EMBs) continue to detect cardiac rejection 
(CR) beyond the first post-transplant year, their need for late CR surveillance is contro- 
versial. However, late CRs are associated with both graft failure and allograft coronary 
disease (ACD). To provide appropriate CR surveillance during late post-transplant peri- 
ods, we assessed the usefulness of non-invasive screenings for both CR diagnosis and 
effective use of EMBs. 
Methods: In 130 patients (post-transplant times: 2- 15 years) monitored routinely by tis- 
sue Doppler imaging (TDI), we compared the diagnostic efficacy of routine EM8s (per- 
formed unrelated to TDI results) with that of diagnostic EM8s (timed by TDI). Routine 
EMBs were performed in 98 patients during annual follow-up catheterizations. Diagnostic 
EMBs, conducted whenever TDI detected left ventricular wall motion alteratlons (prolon- 
gation of relaxation time and/or reduction of systolic and/or diastolic peak velocities), 
were performed in 32 patients. 
Results: Most routine EMBs (89.9%) were ISHLT grade 0 and TDI performed before 
showed no CR relevant changes. CRs grade IA and 1 B were shown in 8 1% of routine 
EM8s. Two routine EM8s (2%), obtained from 2 asymptomatic patients with TDI 
changes, showed relevant CRs grade 3A. Among the 38 diagnostic EMBs pelformed 
due to TDI alterations in 32 patients, 7 (18.4%) were ISHLT grade 0. but I” 5 cases the 
coronary angiogram showed either new appearance or aggravation of ACD. The other 
3ldiagnostic EMBs showed cellular CRs of different degrees (32.3% 1A and lB, 9.8% 
grade 2, 57.9% 3A and 38). Vascular reactions were detectable in 22 diagnostic EMBs. 
Reduction with >15% of systolic velocity Sm, evident in 81.8% of all patients with CR, 
was shown I” all patients with clirwally relevant CRs (ISHLT 2 grade 2 plus IA and 18 
accompanied by hemodynamic deterioration and/or vascular rejections). 
Conclusions: Routine annual EMBs detect only a fraction of relevant CRs which occur 
late after transplantation. Serial TDI screenings followed by diagnostic EMBs, whenever 
relevant wall motion alterations are detected, increase the efficacy of CR diagnosis and 
provide a tempting strategy for late post-transplant CR surveillance. 
1185-85 Noncultured Autologous Skeletal Muscle Cells Can 
Successfully Engraft in Ovine Myocardium 
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Christian Pinset, FranCois Laborde, Didier Montarras, CERA Centre d’ Experimentation 
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Background: The concept of myogenic cell transplantation into the myocardium, known 
as cellular cardiomyoplasty (CCM). is based on the contribution of exogenous cells to 
replace lost or altered cardiomyocytes in order to restore functional performances of the 
heart. There is a large body of evidence showing that CCM performed with skeletal mus- 
cle cells can improve cardiac function in ischemic heart disease as well as dilated cardi- 
omyopathy on numerous animal models. Most research teams have addressed 
autologous CCM in a three phase process : biopsy, ex viva cell culture/expansion and 
surgical or catheter based cell delivery Considering the potential benefit of using non 
cultured muscle cells (little time, lower cost, reduced risk of contamination), we investi- 
gated the feasibility of grafting cells obtained directly after enzymatic dissociation of skel- 
etal muscle biopsies in ovine myocardium.We hypothesized that those non cultured 
muscle cells would massively engraft Methods: Autologous intramyccardlal skeletal 
muscle cells implantation was carried out in 8 sheep. A skeletal muscle biopsy (about IO 
g) was explanted from each animal. The sheep were left to recover over approximately 
three hours and reanesthetized when the cells were ready for the implantation. A left fifth 
intercostal thoracotomy was performed and 10 epicardial injections of the muscle prepa- 
ration (between IO and 20 million cells) were carried out. All sheep were euthanized 3 
weeks after myocardial implantation. lmmunohistochemistry was performed with mono- 
clonal antibodies to a fast skeletal isoform of myosin heavy chain. Results: Skeletal myo- 
sin heavy chain expression was detected in all slides at 3 weeks after implantation in 8 of 
8 animals, confirming engraftment of skeletal muscle cells. Massive areas of engraftment 
(from 2 to 9 mm in diameter) or discrete loci were noted within the myocardral wall. Con- 
clusions: In conclusion, our results indicate that non-cultured skeletal muscle cells can 
successfully and massively engraff in ovine myocardium. Thus, skipping the cell culture 
expansion phase is feasible and could become a promising option for cellular cardiomyo- 
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Son, Dong-Woon Kim, Seung-Taik Kim, Myeong-Chan Cho, College of Medicine, 
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Bone marrow-derived stem cells including mesenchymal stem cells (MSCs) have 
attracted attention as potential platforms for the delivery of therapeutic genes. Lentiviral 
vectors are promising tools for the development of gene therapy since they can trans- 
duce both quiescent and dividing cells. We have previously demonstrated that MSCs can 
be differentiated into cardiomyocytes and restoration of blood flow is crucial for the fate of 
